A phase I/IIa study demonstrated that CV9103, a self-adjuvant mRNA PCa vaccine containing the coding antigens PSA, PSCA, PSMA, and STEAP1, was well-tolerated and immunogenic in patients with CRPC. Here, STEAP1 is linked to posterior cortical atrophy.